PMID: 8610634Apr 1, 1996Paper

Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer

American Journal of Clinical Oncology
S C RemickG R Harper

Abstract

We conducted a multiinstitutional phase II clinical trial to determine the toxicity, response, and survival rate of concurrent 72-h continuous infusion of etoposide and cisplatin in patients with metastatic breast cancer. A total of 26 women were enrolled, 4 of whom received no prior chemotherapy for metastatic disease. All patients were evaluated for toxicity, response, and survival employing the National Cancer Institute (NCI) Common Toxicity Criteria and the Eastern Cooperative Oncology Group (ECOG) response criteria. A total of 84 cycles of therapy were administered, median 3 (range 1 to 6). Severe grade 3 and grade 4 neutropenia occurred in 22 cycles (26%), and there were only 11 episodes (11%) of similar grade thrombocytopenia. Nausea and vomiting were seen in one third of cycles. A single patient (4%) had a complete remission, and seven patients (27%) had partial remissions for an overall objective response rate of 31% (95% confidence interval, 13 to 49%). Three of four patients (75%) without prior therapy for metastatic disease had objective responses. Median survival was 7 months. This combination regimen is active in extensively treated patients with metastatic breast cancer. It is responsible to further investigate t...Continue Reading

References

Mar 1, 1979·Clinical Pharmacology and Therapeutics·P E GormleyR Cysyk
May 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Jul 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T CreaganJ S Kovach
Jan 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K EvansG DeBoer
Mar 14, 1985·The New England Journal of Medicine·P J O'DwyerR E Wittes
Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K EvansG Deboer
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G W SledgeL H Einhorn
Oct 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D F Hayes, I C Henderson
Sep 15, 1970·International Journal of Cancer. Journal International Du Cancer·H C Harder, B Rosenberg
Jun 1, 1982·American Journal of Clinical Oncology·A A ForastiereR E Wittes
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·F C SchellL Esparza
Jun 1, 1982·Cancer Treatment Reviews·W AchterrathP Hilgard
Nov 1, 1982·Cancer Genetics and Cytogenetics·R Becher, A A Sandberg
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone

❮ Previous
Next ❯

Citations

Feb 10, 2004·Cancer Treatment Reviews·M P DecatrisK J O'Byrne
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M ClemonsA Howell
Dec 16, 2003·Breast Cancer Research and Treatment·Anne-Renee HartmanFrank E Stockdale
Mar 20, 2002·Clinical Breast Cancer·M Martín
Nov 26, 2008·Journal of Chemotherapy·F MeriggiA Zaniboni
Jan 18, 2012·Chemotherapy·Ali I Shamseddine, Fadi S Farhat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.